An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis (2007-08-31)

clinical trial

Details

Instance of: clinical trial
Start time: August 2007
End time: October 2010
Country: Australia, Austria, Belgium, Bulgaria, Canada, Czech Republic, Denmark, France, Germany, Hungary, India, Israel
Main subject: golimumab, colitis
clinical trial phase: phase II clinical trial, phase III clinical trial
contributor to the creative work or subject: Merck Sharp & Dohme
minimum age: 18
number of participants: 1065
study type: interventional study
title: A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis

Nothing in the MetaHistoryBook collection references this item yet.